4//SEC Filing
Smith Hunter C 4
Accession 0001104659-25-055974
CIK 0001649904other
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 4:15 PM ET
Size
11.3 KB
Accession
0001104659-25-055974
Insider Transaction Report
Form 4
Smith Hunter C
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-05-30$61.52/sh−18,993$1,168,495→ 109,929 total - Exercise/Conversion
Stock Options (Right to Buy)
2025-05-30−23,400→ 77,194 totalExercise: $6.88Exp: 2027-08-08→ Common Stock (23,400 underlying) - Sale
Common Stock
2025-05-30$60.93/sh−4,407$268,515→ 128,922 total - Exercise/Conversion
Common Stock
2025-05-30$6.88/sh+23,400$160,992→ 133,329 total
Footnotes (4)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $60.33 to $61.32 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $61.33 to $61.62 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The stock option is fully vested.
Documents
Issuer
RHYTHM PHARMACEUTICALS, INC.
CIK 0001649904
Entity typeother
Related Parties
1- filerCIK 0001636385
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 4:15 PM ET
- Size
- 11.3 KB